Table 4.

Age-adjusted Cox models of major CVD^* stratified by COMT SNP genotype within the three drug treatment arms compared to the placebo allocated arm (reference).

Genotype Stratum	Treatment Arm (HR[95%CI], p-value)†				Drug int. p‡
	Placebo	Aspirin only	Vitamin E only	Aspirin + Vitamin E
rs4680
met/met	ref.	0.60 [0.39-0.93], 0.02	0.53 [0.34-0.84], 0.006	0.80 [0.53-1.21], 0.30	0.006
val/met	ref.	0.89 [0.63-1.27], 0.52	1.06 [0.76-1.49], 0.73	0.91 [0.64-1.29], 0.58	0.85
val/val	ref.	1.85 [1.05-3.25], 0.03	1.50 [0.83-2.70], 0.18	1.54 [0.87-2.74], 0.14	0.15
rs4818
C/C	ref.	0.69 [0.47-1.00], 0.05	0.67 [0.46-0.98], 0.04	0.77 [0.53-1.12], 0.17	0.08
G/C	ref.	0.81 [0.56-1.18], 0.28	1.04 [0.73-1.47], 0.85	1.02 [0.72-1.46], 0.89	0.44
G/G	ref.	2.98 [1.45-6.09], 0.003	1.81 [0.84-3.93], 0.13	1.67 [0.77-3.63], 0.19	0.02

^*Major CVD, the primary WHS outcome is a composite of myocardial infarction, stroke or death from cardiovascular causes.

^†Hazard ratio[95%CI] and p-value for each genotype by drug strata relative to placebo in age-adjusted models.

^‡Drug Interaction p-value for interaction of aspirin and vitamin E across all three drug allocations within each SNP genotype stratum relative to placebo.